Mark Warner Discusses Implications for Canada from President Trump’s Drug Import Proposals

Published by: Mark Warner 1 August, 2019 Categories Tags

Mark Warner was interviewed on Newstalk 1010 about President Trump’s proposals to facilitate certain pharmaceutical imports from Canada to the United States. (August 1, 2019) Mr. Warner was Legal Director of the Ontario Ministry of Economic Development & Trade and advised Ontario in the negotiation of the Canada – EU Trade Agreement (CETA) including on drug pricing and patent appeals and on other trade and investment negotiation and dispute settlement matters including NAFTA . Mr. Warner, a Canadian and U.S. lawyer, has advised pharmaceutical companies on pricing, distribution and other competition and trade matters. Mr. Warner has also governments on trade policy and trade negotiations and previously worked on trade and competition issues as counsel in the OECD Trade Directorate.

Mark Warner

About Author

Mark is a business-oriented, results-driven, senior international business and regulatory law expert with private practice, government, academic, in-house and legal management experience in Canada, the United States, Europe and major emerging markets. He has extensive in cutting-edge experience in providing strategic legal advice to clients in on high impact / high profile competition, trade, investment, regulatory and corporate / commercial matters and providing compliance training to businesses and technical assistance to governments. Career highlights include leading the Government of Ontario’s legal team in relation to restructuring of GM & Chrysler, advising a multinational pharmaceutical company on distributing its HIV / AIDS drugs globally, and leading a team of foreign lawyers to draft the new South African Competition Law, a key framework economic policy for post-Apartheid South Africa.

Mark Warner Discusses Implications for Canada from President Trump’s Drug Import Proposals

About Author

Contact

Menu